ATC code J05

ATC codes

J Antiinfectives for systemic use

J01 Antibacterials for systemic use

J02 Antimycotics for systemic use

J04 Antimycobacterials

J05 Antivirals for systemic use

Human only

J06 Immune sera and immunoglobulins

J07 Vaccines

ATCvet only

QJ51 Antibacterials for intramammary use

QJ54 Antimycobacterials for intramammary use

ATC code J05 Antivirals for systemic use is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the WHO for the classification of drugs and other medical products. Subgroup J05 is part of the anatomical group J Antiinfectives for systemic use.^[1]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ05.^[2]

National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

J05A Direct acting antiviral drugs

J05AA Thiosemicarbazones

J05AA01 Metisazone

J05AB Nucleosides and nucleotides excluding reverse transcriptase inhibitors

J05AB01 Aciclovir

J05AB02 Idoxuridine

J05AB03 Vidarabine

J05AB04 Ribavirin

J05AB06 Ganciclovir

J05AB09 Famciclovir

J05AB11 Valaciclovir

J05AB12 Cidofovir

J05AB13 Penciclovir

J05AB14 Valganciclovir

J05AB15 Brivudine

J05AB54 Ribavirin, combinations

J05AC Cyclic amines

J05AC02 Rimantadine

J05AC03 Tromantadine

J05AD Phosphonic acid derivatives

J05AD01 Foscarnet

J05AD02 Fosfonet

J05AR05 Zidovudine, lamivudine and nevirapine

J05AR06 Emtricitabine, tenofovir disoproxil and efavirenz

J05AR07 Stavudine, lamivudine and nevirapine

J05AR08 Emtricitabine, tenofovir disoproxil and rilpivirine

J05AR09 Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat

J05AR10 Lopinavir and ritonavir

J05AR11 Lamivudine, tenofovir disoproxil and efavirenz

J05AR12 Lamivudine and tenofovir disoproxil

J05AR13 Lamivudine, abacavir and dolutegravir

J05AR14 Darunavir and cobicistat

J05AR15 Atazanavir and cobicistat

J05AR16 Lamivudine and raltegravir

J05AR17 Emtricitabine and tenofovir alafenamide

J05AR18 Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat

J05AR19 Emtricitabine, tenofovir alafenamide and rilpivirine

J05AX Other antivirals

J05AX01 Moroxydine

J05AX02 Lysozyme

J05AX05 Inosine pranobex

J05AX06 Pleconaril

J05AX07 Enfuvirtide

J05AX08 Raltegravir

J05AX09 Maraviroc

J05AX10 Maribavir

J05AX11 Elvitegravir

J05AX12 Dolutegravir

J05AX13 Umifenovir

J05AX14 Daclatasvir

J05AX15 Sofosbuvir

J05AX16 Dasabuvir

J05AX65 Sofosbuvir and ledipasvir

J05AX66 Dasabuvir, ombitasvir, paritaprevir and ritonavir

J05AX67 Ombitasvir, paritaprevir and ritonavir

References

↑ "ATC/DDD Index 2016: code J05". WHO Collaborating Centre for Drug Statistics Methodology.
↑ "ATCvet Index 2016: code QJ05". WHO Collaborating Centre for Drug Statistics Methodology.

DNA virus antivirals (primarily J05, also S01AD and D06BB)

Baltimore I

Herpesvirus

DNA-synthesis
inhibitor

TK activated

Purine analogue	guanine (Aciclovir^#/Valaciclovir Ganciclovir/Valganciclovir Penciclovir/Famciclovir) adenine (Vidarabine)

Pyrimidine analogue	uridine (Idoxuridine Trifluridine (+tipiracil) Edoxudine) thymine Brivudine Sorivudine cytosine (Cytarabine)

Not TK activated

Foscarnet

Other

HPV/MC

Vaccinia

assembly: Rifampicin

Poxviridae

Methisazone

Hepatitis B (VII)

Multiple/general

Nucleic acid inhibitors	Cidofovir

Interferon	Interferon alfa 2b Peginterferon alfa-2a

Multiple/unknown	Ribavirin^#/Taribavirin^† Moroxydine

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir Faldaprevir^‡ Grazoprevir Paritaprevir Simeprevir Telaprevir

NS5A inhibitors (–asvir)	Daclatasvir Elbasvir Ledipasvir MK-3682 MK-8408 Odalasvir^† Ombitasvir Ravidasvir^† Samatasvir^† Velpatasvir

NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir^† Dasabuvir Deleobuvir^§ Filibuvir^§ Setrobuvir^§ Sofosbuvir Radalbuvir^†

Combination drugs	Elbasvir/grazoprevir Ledipasvir/sofosbuvir Ombitasvir/paritaprevir/ritonavir Sofosbuvir/daclatasvir Velpatasvir/sofosbuvir

Picornavirus

viral entry: Pleconaril^†

Anti-influenza agents

Umifenovir

neuraminidase inhibitors/release phase (Oseltamivir
Zanamivir
Peramivir, Laninamivir^†)

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a^#

Multiple/unknown	BCX4430^† Favipiravir GS-5734^† Mericitabine^† MK-608^§ NITD008^§ Moroxydine Ribavirin^#/Taribavirin^† Triazavirin

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Entry/fusion inhibitors
(Discovery and development)

gp41 (Enfuvirtide (ENF, T-20))
CCR5 (Maraviroc (MVC)
Vicriviroc^†, Cenicriviroc^†, PRO 140^†)
CD4 (Ibalizumab^†)
gp120 (Fostemsavir^†)

Reverse-transcriptase
inhibitors (RTIs)

Nucleoside and nucleotide (NRTI)	Nucleoside analogues/NRTIs: Abacavir (ABC)°^# Didanosine (ddI) Emtricitabine (FTC)° Lamivudine (3TC)°^# Stavudine (d4T)^# Zidovudine (AZT, ZDV)^# Amdoxovir^† Apricitabine^† Censavudine^† Elvucitabine^† Racivir^† Stampidine^† Zalcitabine (ddC)^◊ Nucleotide analogues/NtRTIs: Tenofovir disoproxil (TDF)°^# Tenofovir alafenamide (TAF)

Non-nucleoside (NNRTI) (Discovery and development)	(1st generation) Efavirenz (EFV)°^# Nevirapine (NVP)^# Delavirdine (DLV)^◊ (2nd generation) diarylpyrimidines (Etravirine (ETR) Rilpivirine (RPV)°) Doravirine

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Dolutegravir (DTG)°
Elvitegravir (EVG)°
Raltegravir (RAL)°
BI 224436^†
Globoidnan A (experimental)
Cabotegravir^†
Bictegravir^†
MK-2048^†

Maturation inhibitors

Bevirimat^†
BMS-955176^§

Protease Inhibitors (PI)
(Discovery and development)

1st generation	Amprenavir (APV)^◊ Fosamprenavir (FPV) Indinavir (IDV)^◊ Lopinavir (LPV) Nelfinavir (NFV) Ritonavir (RTV)^# Saquinavir (SQV)^#

2nd generation	Atazanavir (ATV)°^# Darunavir (DRV)°^# Tipranavir (TPV)

Combined formulations

Abacavir/lamivudine°^#
Abacavir/dolutegravir/lamivudine°
Abacavir/lamivudine/zidovudine
Atazanavir/cobicistat
Darunavir/cobicistat
Efavirenz/emtricitabine/tenofovir°^#
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Elvitegravir/cobicistat/emtricitabine/tenofovir°
Emtricitabine/tenofovir alafenamide
Emtricitabine/rilpivirine/tenofovir alafenamide
Emtricitabine/rilpivirine/tenofovir°
Lamivudine/raltegravir
Lamivudine/zidovudine^#
Lopinavir/ritonavir°^#
Tenofovir/emtricitabine°^#

Pharmacokinetic boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)

Transcription inhibitors	Tat antagonists

Translation inhibitors	Trichosanthin

Other	Abzyme BIT225^† Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) KP-1461^† Foscarnet Fosdevirine^† Griffithsin Hydroxycarbamide Miltefosine Portmanteau inhibitors Scytovirin Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor

Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

°DHHS recommended initial regimen options. ^◊Formerly or rarely used agent.

This article is issued from Wikipedia - version of the 1/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.

ATC code J05

J05A Direct acting antiviral drugs

J05AA Thiosemicarbazones

J05AB Nucleosides and nucleotides excluding reverse transcriptase inhibitors

J05AC Cyclic amines

J05AD Phosphonic acid derivatives

J05AE Protease inhibitors

J05AF Nucleoside and nucleotide reverse transcriptase inhibitors

J05AG Non-nucleoside reverse transcriptase inhibitors

J05AH Neuraminidase inhibitors

J05AR Antivirals for treatment of HIV infections, combinations

J05AX Other antivirals

References